Picture EBD Group BIO-Europe 2020 Digital Event BEU2020 650x81
Organisation › Details

Dinaqor AG

DiNAQOR’s mission is to develop gene therapy solutions that transform the lives of patients with heart disease. Our novel and innovative gene therapy platform is focused on advancing treatments for patients affected by genetic cardiomyopathies, a disease of the heart muscle that can lead to heart failure. We were founded in April 2019 by a team of leading pharmaceutical and biotechnology executives and academics with deep cardiology and gene therapy expertise. We have established strategic partnerships with leading institutions and companies including Lonza and University Medical Center Hamburg-Eppendorf to advance our cardiac gene therapy platform and pipeline. Our company is headquartered in Pfäffikon, Switzerland, with additional presence in London, England and Boston, Massachusetts. *


Period Start 2019-04-01 established
  Group Dinaqor (Group)
Products Industry gene therapy
  Industry 2 cardiology
Person Person Holzmeister, Johannes (Dinaqor 202009 CEO + Co-Founder + Cardiorentis AG 201409 CEO + CMO)
Region Region Pfäffikon SZ
  Country Switzerland
  Street 77 Churerstr.
  City 8808 Pfäffikon SZ
    Address record changed: 2020-09-20
Basic data Employees n. a.
    �About Section� taken from web site of organisation on 17.09.
Record changed: 2020-09-20


Picture ConsulTech GmbH GDPR-compliant E-Col Cloud Document Management 650x80px

More documents for Dinaqor (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture EBD Group BIO-Europe 2020 Digital Event BEU2020 650x81

» top